Sun Pharma Share Price Target 2026: Sun Pharmaceutical Industries Ltd. share price will remain in focus after brokerages largely retained a positive stance following its Q4FY26 results, highlighting growth in India and specialty segments despite margin pressures. The company reported a strong 26 per cent year-on-year rise in profit, and several analysts see potential upside of up to 12 per cent in the stock, even as some flagged higher costs and weakness in the US generics business as near-term concerns.
Goldman Sachs on Sun Pharma
Morgan Stanley on Sun Pharma
Sun Pharma reported a upbeat results for the fourth quarter of FY26, with consolidated net profit rising 26.2 per cent year-on-year to Rs 2,714 crore from Rs 2,149.8 crore in the same period last year. The company’s revenue grew 12.8 per cent YoY to Rs 14,612 crore, while EBITDA increased 6.4 per cent to Rs 3,954 crore. However, EBITDA margins contracted to 27.1 per cent from 28.7 per cent a year ago, broadly in line with estimates. The board has recommended a final dividend of Rs 5 per share.
The company’s growth was supported by strong performance across key markets. Global Innovative Medicines sales rose 20.1 per cent to USD 354 million, while India formulations, contributing 33.2 per cent of total sales, , grew 14.8 per cent to Rs 4,835.9 crore. Emerging markets formulations also remained a key driver, rising 17.4 per cent to USD 306 million and accounting for 19 per cent of consolidated sales. Meanwhile, US formulations sales saw a marginal decline of 1.1 per cent to USD 459 million, and Rest of the World formulations grew 10 per cent to USD 220 million.
Sun Pharma continued to invest in research and development, with R&D spending at 6.7 per cent of sales in Q4 and 6.1 per cent for the full year. The company also strengthened its innovation pipeline with the launch of products like Leqselvi and Unloxcyt during FY26. With a robust net cash position of USD 3.2 billion.
(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money related decisions.)
